Dr. Elsa Abranches joined the UK Stem Cell Bank team in December 2015 as a Senior Stem Cell Biologist. In January 2019, Dr. Elsa was appointed Group Leader of the Section of Stem Cell Biology and Director of the UK Stem Cell Bank. Her primary focus is developing and delivering a programme of...

My research focuses on tumor immunology, chimeric antigen receptor (CAR) T-cell therapy, and combination immunotherapy for solid tumors. Over the years, our research has yielded mechanistic data that has been translated to CAR T-cell and combination immunotherapy clinical trials for patients with...

In 2000, after roles in the pharmaceutical and diagnostics industry, she created the Tech and Transfer Office of the Hospitals of Paris (AP-HP), that she managed and developed for 16 years. Over this period of time, more than 70 biotech, meditech and ehealth startups were launched as part of an...

Eric is Professor of Gene Therapy and Respiratory Medicine at Imperial College, London, an Honorary Consultant Physician at the Royal Brompton Hospital and NIHR Senior Investigator. Over the last 20 years he has coordinated the UK Cystic Fibrosis Gene Therapy Consortium, which brings together all...

Dr. Steven M. Altschuler currently serves as Managing Director-Healthcare Ventures at Ziff Capital Partners and Chair, Board of Directors of Spark Therapeutics. At Ziff Capital Partners, he leads firm’s effort to start up new companies at the intersection of machine learning and cellular and...

Dr. Stephen Badylak, DVM, PhD, MD is a Professor in the Department of Surgery, and Deputy Director of the McGowan Institute for Regenerative Medicine at the University of Pittsburgh. He has practiced both veterinary and human medicine and is now fully engaged in research. Dr. Badylak began his...

Stefano Baila received his PhD in 2007 based upon translational research and development of gene therapies for hemophilia at the Children’s Hospital of Philadelphia.  Since that time he has been actively involved in the process development and manufacturing of advanced therapeutic medicinal...

Cynthia Bamdad is the CEO of Minerva Biotechnologies. Dr. Bamdad holds a BS in Physics from Northeastern University and a PhD in Biophysics from Harvard University. While a grad student at Harvard, Bamdad invented an electronic DNA chip that sold to Motorola for $300M in 2000, and is now an FDA...

Ricardo P. Baptista is the Director of Process and Analytical Development at Cellectis. Prior to Cellectis, he held the role of Lead Scientist at The Cell and Gene Therapy Catapult, London. He was in charge of Catapult’s programs for developing process and analytical platforms for large-scale...

Dr Ardeshir Bayat trained as a clinician scientist BSc (Hons) MB BS MRCS PhD. His research work is focused on the subject of skin repair, rejuvenation and regeneration. He is considered an international expert in this subject area, having presented and published extensively in this field. His...

Mark Beards is a non-executive director of the company and has over 28 years’ experience in the life sciences and financial sectors within both global organisations and early stage companies. Mark is Chief Executive Officer at Utility Therapeutics He has previously held the role of Corporate...

Francesca Bellintani is a Downstream Process Development Manager at MolMed. Biologist by education she holds a degree in Biology from University of Milan working on overproduction and purification of recombinant proteins; she is specialised in Biochemistry working on Phage display in Cambridge...

I am a scientist by training and hold a PhD in Pharmacology. After my post-doc I got an MBA from HEC Paris. In the business development team of Fondazione Telethon I have been setting-up and following alliances aimed at developing advanced therapies stemming from the Telethon institutes and most...

David Blakey has a degree in Biochemistry from Oxford University, a PhD from London University and then worked as a Post Doc at the ICRF in London. In 1987 he joined AstraZeneca where he championed the company’s move into therapeutic antibodies. He was appointed Chief Scientist in Oncology in 2008...

Axel Boehnke is Director Market Access. He´s fully responsible all market access aspects, patient access as well early evidence planning as well as actions to accelerate access to patients, currently with the focus on orphan diseases and gene therapy. His experience in this area of work has allowed ...

Luis Borges is Chief Scientific Officer at Century Therapeutics where he leads the research and development of genetically engineered iPSCs-derived immune cell products for the treatment of cancer. Century is committed to developing novel off-the-shelf cell products that overcome the limitations of ...

Dr Kieran Breen had an academic career with a focus on Alzheimer’s disease research before working in research funding organisations where he developed new strategic research initiatives. He has served on the review boards for a number of research organisations and has been involved in the...

Dr Amandine Breton is currently a Cell Therapy Operations Manager at Orchard Therapeutics where she supports activities related to the transfer and oversight of manufacturing processes and controls to support Orchard’s product pipeline programs from pre-clinical through to commercialization.  Prior ...

Dr Brooks is a clinical Cardiologist with specialties in advanced cardiac imaging and clinical trial design and execution who trained at Cornell University, Johns Hopkins Hospital and University of California San Francisco. He has accumulated >15 years of clinical and clinical development...

Philip John (P.J.) Brooks is a Program Director in the NCATS Office of Rare Diseases Research (ORDR). Dr. Brooks received his Ph.D. in neurobiology from the University of North Carolina at Chapel Hill. After completing a postdoctoral fellowship at the Rockefeller University, Brooks became an...

A Doctor in Pharmacy, who holds a degree in Health law. He enjoyed a long career in the field of Regulatory Affairs.He began his career as a consultant with International Drug Development (IDD), but soon joined the company SYNTHELABO in its Research and Development center where he worked for nine...

Iain is a passionate clinical educator and leads our clinical nursing team. Working for large homecare providers has allowed Iain to develop expert clinical knowledge of wide ranging therapy areas. Leading by example Iain prides himself in remaining clinically competent, demonstrating the...

Bradley L. Campbell is the President and Chief Operating Officer of Amicus Therapeutics (NASDAQ: FOLD) and is also a member of the Board of Directors. He brings nearly 20 years of experience in the Orphan Drug industry. Mr. Campbell joined Amicus in 2006 and leads the global organization...

Chemical Engineer, 1971, Univ. Porto; Master of Sciences (1975) and PhD in (1979) Environmental Engineering, Imperial College of Science and Technology, U. London; Habilitation in, Biochemical Engineering (1991), NOVA-Univ. Nova de Lisboa. Full Professor, Chemical and Biochemical...

Angela Columbano has over 20 year experience in the pharmaceutical and Biomedical industry. Prior to Genethon, Angela was Principal at Sanofi Sunrise an early investment and partnering vehicle. Angela has also held various positions with Sanofi in Marketing and Business Development and Licensing...

Jean-Philippe has 28 years of experience in the pharma & biotech industries. He is a highly skilled senior executive with a broad range of experience leading global development and a successful track record of partnership, innovation and development in the area of Orphan Drugs. Co-Founder of...

I started my career as a Research associate at Novartis, before undertaking a PhD in Medical and Surgical Sciences at Nottingham University. I then subsequently spent 3 years as a Heart and Stroke Foundation postdoctoral fellow at the University Calgary, Canada before joining ReNeuron as a senior...

I am Biomedical Engineer from Politecnico of Milano (Italy). During my career I collaborated with the Australian Institute of Bioengineering and Nanotechnology at the University of Queensland (Australia) investigating the differentiation of mesenchymal stem cells in a microfluidic device. After my...

Prior to joining Tmunity, Dr. Coughlin was Chief Medical Officer at British biotechnology company, Immunocore Ltd., where she was responsible for leading the effort to develop novel bispecific T cell receptor-based biologics for cancer immunotherapy. Dr. Coughlin led the clinical efforts and...

Chandler Crews has a passion for writing and public speaking. Born with the most common form of dwarfism, achondroplasia, she grew up limited when it came to her own independence. Imagining what her life would have been like if she were able to see and experience the world the way most people...

Dr. Cruz is developing immune cell-based therapies for cancer and HIV. His work is focused on T cells and NK cells – experimentally tractable cells of the adaptive and innate immune response, respectively, that have been used in the clinics. His laboratory is focused on different ways of developing ...

Davide Danovi holds an MD from University of Milan and a PhD in Molecular Oncology from the European Institute of Oncology where he demonstrated the causative role of the HdmX protein in human cancer. He completed his postdoctoral training working with Prof. Austin Smith and Dr. Steve Pollard at...

Eric Michael David is CEO of gene therapy at BridgeBio. He was a co-founder of Organovo, where he most recently served as Chief Strategy Officer and Executive Vice President of Preclinical Development. Prior to Organovo, Dr. David was an Associate Partner at McKinsey & Co, where he served...

Johannes P.J.M. de Munter is a trained physician and a registered scenario-epidemiologist with more than 35 years of experience in medical health care. He started as emergency health care physician, general practitioner and specialist infectious diseases, and worked for 15 years as deputy director...

Joe Dupere was appointed as Chief Executive Officer of Rexgenero in February 2015. Joe has more than 20 years of business development, M&A, operational and research management experience in the biopharmaceutical and investment banking sectors. Prior to Rexgenero, Joe was Head of Business...

Dominik Egger received his bachelor degree in Life Science at the University of Hannover in 2011 and continued with the master degree in the same field. During the master studies he was granted a fellowship to study at the Institute of Life Sciences of the Hebrew University of Jerusalem. In 2013 he ...

Victoria English, the editor, is a former financial journalist for Dow Jones and Reuters having worked in New York, Amsterdam, Brussels and London. In 1997 she began writing about healthcare at Reuters, and later joined Scrip to cover the pharmaceutical industry. From Scrip, she became editor of...

Rajvinder Karda, Joanne Ng and Antoine is the CEO of MicrofluidX. He is an engineer by training (PhD in Engineering from Cornell University, USA), and has over 3 years of experience in CGT and CGT manufacturing. He has designed, prototyped and tested several microfluidic devices for cell...

Farzin Farzaneh, Professor of Molecular Medicine, Kings College London Having studied at universities of Aberdeen and Sussex, followed by a number of fellowships by Beit, EMBO and MRC, in UK and Holland, I Joined King's College London in 1985. I was appointed the founding head of the Department ...

Thomas Mørch Frøsig, PhD, CEO/CSO and cofounder of ImmuMap, has successfully established the company as a key player in advanced monitoring of cellular immunity. Dr. Frøsig did his PhD on methods for T cell epitope discovery at the Danish Center for Cancer Immune Therapy/University of Copenhagen...

Thomas Mørch Frøsig, PhD, CEO/CSO and cofounder of ImmuMap, has successfully established the company as a key player in advanced monitoring of cellular immunity. Dr. Frøsig did his PhD on methods for T cell epitope discovery at the Danish Center for Cancer Immune Therapy/University of Copenhagen...

Michela Gabaldo is Head, Alliance Management & Regulatory Affairs at Fondazione Telethon in Milan, Italywhere she joined in 2011.As Head of Alliance Managment she was responsible for the execution of the first strategic Alliance ofTelethon/OSR with GSK managing gene therapy projects at...

Dr. Chiara Gai earned a PhD in Medical Pathophysiology from the Department of Medical Sciences of the University of Turin in 2017. Dr. Gai is working with Prof. Camussi since 2014 in the field of EV derived from stem cells. She set up several in vitro tests for the assessment of the minimal...

1991 – to date             BioPlanta GmbH President and CEO● Development and Manufacturing of stem cell products● Clinical Trial and Licensing of stem cell pharmaceuticals and tissue   engineered products 2017 – 2018             Bergmann AG Chief Business Development Officer; since 12/2017 Chief    ...

Dr. David Gilham is Vice-President R&D of Celyad. He heads the implementation of Research and Development strategy for the immune-oncology programs. Dr. Gilham received his Ph.D in Molecular Pharmacology at the University of Dundee prior to moving to Bristol University in 1996 to work on CAR T...

Paul Gissen is the Head of the Genetics and Genomic Medicine Department at the UCL Great Ormond Street Institute of Child Health, London, UK, Honorary Consultant in paediatric metabolic diseases at Great Ormond Street Hospital for Children NHS Foundation Trust, Deputy Lead for Novel Therapies theme ...

Dr. rer. nat. Dipl. Ing. Matthias Goßmann holds a diploma in biotechnology and a doctorate degree in chemistry. Since 2008, he has been working on the development of a new technology to measure cardiac contraction force within a flexible environment. He gained 3.5 years of experience as senior...

Cecilia Götherström is an Associate Professor in Stem Cell Research at Karolinska Institutet in Sweden and her research is in the field of perinatal regenerative medicine. Dr Götherström has developed fetal mesenchymal stem cells for prenatal and postnatal transplantation purposes and since then...

Julian is a biotech entrepreneur and world expert in bioinformatics. He graduated his PhD in molecular biology from the University of Cambridge and was a research fellow at Stanford University. He is now a Programme Leader at the MRC Laboratory of Molecular Biology in Cambridge and Professor of...

Lise Marie Grav is a postdoctoral researcher at the Novo Nordisk Foundation Center for Biosustainability at the Technical University of Denmark. She graduated with a Ph.D. in biotechnology in early 2018 from the same university and has worked in the field of CHO cell line engineering and...

How the role of patient organizations is changing in the drug development process A case study from the Charcot-Marie-Tooth Association in acceAmy J Gray is the CEO of the Charcot-Marie-Tooth Association. Since taking over as CEO in May of 2017, the CMTA has grown substantially under Amy’s...

2018-        Chief Scientific Officer and Head of Production        RheinCell Therapeutics GmbH, Langenfeld, Germany2012-2017    Independent Research Group Leader Max Planck Institute for Molecular Biomedicine, Münster, and Chemical Genomics Centre of the Max Planck...

Dave Greenwald, Ph.D. currently serves as Vice President, Business Development at Deerfield Management. In this role, Dr. Greenwald searches for new investment opportunities, supports business development of the Deerfield portfolio companies, and provides hands-on experience to Deerfield’s academic ...

Uta Griesenbach is a Professor in Molecular Medicine at the National Heart and Lung Institute, Imperial College London and the President of the British Society for Gene and Cell Therapy (www.bsgct.org/). Uta‘s reserach interests are related to the development of gene therapy-based treatments for...

Brad is the co-founder and CSO of GoodCell and is responsible for the scientific programs and technologies employed within the company. Prior to joining GoodCell, Brad was the Chief Technology Officer for ReproCELL, Inc., a multinational stem cell company focused on the development of novel stem...

Stephen Hart obtained his PhD in Microbiology from the University of Cape Town in 1991 then undertook a postdoc at St. Mary’s Biochemistry and Molecular Genetics Department before joining the UCL Great Ormond Street Institute of Child Health (ICH) as a postdoc then Lecturer. He was promoted to...

Hansjörg Hauser’s expertise is molecular biology. He is studying events in transcription activation and signal transduction that mediate consequences of infections. With this work he tries to connect molecular events of innate immune reactions with complex phenotypes in the organism. He is also...

Frank Hecht joined CellGenix in 2014. As Vice President of Marketing and Sales he is responsible for the management of the worldwide customer-facing activities and the strategic marketing positioning of the company.  Frank Hecht holds a Master’s Degree in Biology from the University of...

Chris Heery, MD, is the Chief Medical Officer at Precision BioSciences. Prior to joining Precision, Dr. Heery served as Chief Medical Officer of Bavarian Nordic where he oversaw clinical development programs for its immune-oncology and infectious diseases portfolios. Prior to this, he was Head of...

Asael  is Emendo’s CTO. He has over 20 years of experience in protein engineering and is an expert in the directed molecular evolution approach. Prior to joining Emendo he led the R&D of Smartzyme Biopharma. He formerly was the VP of R&D at Biolojic Design, an antibodies engineering...

Christoph Herwig, bioprocess engineer from RWTH Aachen, worked in industry in the design and commissioning of large chemical facilities prior to enter his interdisciplinary PhD studies at EPFL, Switzerland in bioprocess identification. Subsequently he positioned himself at the interface between...

Edward Hodgkin is a Partner of Syncona Partners LLP and a Non-Executive Director of Autolus Ltd, where he served as CEO from the company’s inception in September 2014 until March 2016. Autolus is developing a series of next-generation engineered T-cell products for treatment of haematological and...

Dr. Johnny Huard is a world-renowned scientist and is currently the Chief Scientific Officer and Director of the Center for Regenerative Sports Medicine at the Steadman Philippon Research Institute (SPRI) in Vail, Colorado. Before moving full time to Vail, Dr. Huard was the Distinguished Professor...

Michael Hunt joined ReNeuron in 2001. Between 2005 and 2014 he served as its CEO, leading the business through its early development to its current position as one of the global, clinical-stage leaders in the regenerative medicine field. He was appointed Chief Financial Officer in 2014.He is a...

Dejan Hušman is the CEO of denovoMATRIX, a biotech spin-out from the TU Dresden in Germany. Dejan has a background in Molecular Bioengineering and Biomaterials, having completed his PhD in Dresden, in the group of Prof. Carsten Werner. Following his studies, began his work on denovoMATRIX -...

Dr. Moshe Israeli serves as the director of the tissue typing laboratory of the Beilinson Hospital, Rabin Medical Center in Israel. In his clinical duty Dr. Israeli is responsible for all immuno-genetic diagnostic testing of all organ and stem cell transplants carried out by the Clalit Health...

Dr. Jain is the Chief Operating Officer for Twin City Bio/inRegen, a cell-based therapy company and has over 39 years of experience in biotechnology, tissue engineering, cell therapy and regenerative medicine bioprocess research & development and GMP manufacturing. Twin City Bio/inRegen is...

Dr Agnieszka Janeczek has an extensive scientific track record in tissue engineering and regenerative medicine and developed a passion for the business aspects of innovation. She co-founded Renovos in 2017 and is leading on the business development and operational side of the Southampton...

Rob Jones is an accomplished supply chain executive with 29 years of commercial development experience and 10 years’ experience in the blood transfusion industry. Qualified in Hematology and Blood Transfusion Medicine, he originally worked at the UK National Blood Service at the Birmingham...

Troels Jordansen started his career in healthcare with Leo Pharmaceutical Product and after 4 years with Johnson & Johnson Orthopaedics was one of the initial Genzyme Europe hires to focus on commercialising Carticel and Epicel in 1996. Over the last 20 years Troels has worked for 5 different...

Steve is the Chief Scientific Officer of Caribou Biosciences responsible for R&D activities related to therapeutic discovery and development.  Before joining Caribou, Steve served in positons of increasing responsibility in both oncology and immunology/inflammation drug discovery at...

Cornelia Kasper studied Chemistry at the University Hannover and received her Diploma degree 1994. She performed her dissertation at the Institute for Technical Chemistry 1995-1998 and graduated as Dr. rer. nat.. Until 2000 she was employed as EU liason officer at the University of...

Dr. Jasmin Kee is a process and manufacturing operations specialist with over 15 years’ experience in the Cell and Gene Therapy industry. She has worked for companies including Intercytex, Organogenesis, Reneuron and Cell Medica and now provides consultancy in areas including manufacturing process...

Orion Keifer is a neuroscientist with neurosurgical training and hands-on expertise in small and large animal models, focused small molecule, and cell and gene therapies for neurological diseases. Before joining CODA, he worked as a consultant translational scientist and surgeon for Above and...

Dr. Keirstead is an internationally known stem cell expert and has led therapy development for late stage cancers, immune disorders, motor neuron diseases, spinal cord injury and retinal diseases. He is the CEO of AIVITA Biomedical. He was previously CSO of Caladrius which acquired California Stem...

Paul is co-founder and Chief Executive Officer of HairClone, a cell therapy Company developing cell based treatments for androgenic alopecia. Paul has over 30 years’ experience in the US and UK in the commercialisation of various Regenerative Medicine and Cell Therapy products in both public and...

Seokjoong Kim is an experienced molecular biologist in the field of programmable nuclease development and genome editing technology. Currently, Seokjoong is leading research and business development of ToolGen, Inc., Korean biotech focused on the translation of CRISPR/Cas9 technology into valuable...

Masa (Masahiro KINO-OKA) is one of leaders in the field of manufacturing for cell and tissue products; individuals who seem able to contribute to the standardization of the cell processing facility and bioreactor. His current research interests are “Bioprocess engineering” to establish the cell and ...

Immunologist with focus on infectious diseases, rare diseases and cancer. I received my PhD in 2012 from the University of Hamburg (Germany) and trained as a postdoctoral fellow at the Ragon Institute of MGH, MIT and Harvard in Cambridge, MA. I have studied T cells in the context of...

Dr. Kochan has extensive scientific and management background in early and late clinical development programs in oncology, metabolic disease, cardiovascular, immunology, and inflammation. He has made important contributions in biomarker identification and development, and the application of...

Dr. Sebastian Kress is a postdoctoral scientist at the Institute of Cell and Tissue Culture Technologies at BOKU, Vienna, Austria. His research focuses on non-destructive online monitoring of metabolic parameters and the secretome of 3D cell cultures combining dynamic cultivation systems and...

Maximilian is a trained Downstream Process Engineer. He is currently developing hybrid-models at Novasign GmbH to better describe downstream unit operations aiming to speed up bioprocess development. Simultaneously, he is working on his PhD at the University of Natural Resources and Life Sciences...

Prof. Dr. Jürgen Kuball received his medical degree as hematologist at the University of Mainz, Germany, and was further trained at the Fred Hutchinson Cancer Center in Seattle, WA, USA. Prof. Kuball joined the Department of Hematology at the University Medical Center in Utrecht (UMC Utrecht) in...

Dmitry is the founder and managing partner of 4BIO Capital Partners, a venture capital firm focused on advanced therapies. He trained as a neuroscientist. Before co-founding the firm, Dmitry spent many years doing academic research on optogenetics and gene therapy for CNS disease in Germany and the ...

Dr. Lamb is scientific co-founder, Executive Vice President, and Chief Scientific Officer of Incysus Therapeutics.  As a transplant immunologist with 27 years’ experience in clinical-translational immunotherapy research, he is responsible for first describing the association between relapse-free...

Most recently heading the EMEA Biodevelopment Center of Merck KGaA in France, Michaël Lanero Fidalgo brings to TreeFrog Therapeutics an 18-year experience of senior leadership in the biopharmaceutical industry. Prior to his experience at Merck in transitioning innovative therapies into commercial...

Jane Lebkowski has been actively involved in the development of cell and gene therapies since 1986 and is President of R&D at Regenerative Patch Technologies (RPT), a biotechnology firm developing composite stem cell-based implants targeting restoration of retinal architecture and function in...

Mr. Lebovits joined Brainstorm in July 2007 as President and has been involved with its activities from early pre-clinical stage to the current Phase IIb clinical trials in the United States, and has taken a monumental part in its huge growth and development.Since September 2015, Mr. Lebovits also...

Steven Lee qualified with a BSc in Microbiology from the University of Bristol and went on to study for a PhD at the London School of Hygiene and Tropical Medicine researching immune responses in leprosy patients. He then joined the Institute of Cancer Studies at the University of Birmingham where...

Tongri Liu (Tony) has completed his Ph.D. at the age of 27 years from University of Oxford, UK. He is now the chief overseas representative of Beijing ALLIFE Medicine Science and Technology Co. Ltd., a Chinese Pharmaceutical Company specialised in iPSc derived cell and gene therapies, and the...

Diana started her career in the medical device industry before she came to SCHOTT in June 2018. In her role as Product Manager for bulk vials, she is responsible for the product strategy, including the identification of new market opportunities and the development and launch of innovative products.

Having studied for a degree in Biochemistry and a PhD in Cell Biology, Anthony spent his early career in drug discovery research in academia and the pharmaceutical industry. Anthony entered the ATMPs field in 2009 through a role at UCL Institute of Ophthalmology’s clinical cell therapy unit. He...

Focusing on genome engineering and transgenesis, Friedemann earned his PhD in 2015 from the Erasmus Medical Center in Rotterdam. He followed up by conducting postdoctoral research in the lab of Guido Kroemer at Institut Gustave Roussy and the Centre de Recherche des Cordeliers in Paris. Working at...

Frank Luyten is full professor in the Biomedical Sciences at the KU Leuven, BE and Chairman of the division of rheumatology at the University Hospitals Leuven; Director of the Skeletal Biology and Engineering Research Center, KU Leuven; Director of Prometheus, Division of Skeletal Tissue...

Dr John Maher is a clinical immunologist and immunopathologist who leads the "CAR Mechanics" research group within King's College London. His research group is focused on the development of adoptive immunotherapy using CAR engineered and gamma delta T-cells. He is also chief...

Engineer in Biochemistry from INSA (Lyon-France), he has worked internationally in leader companies developing tools for the Biotechnologies, mainly for the bioprocessing. He managed French companies and developed key accounts worldwide. Recently, he successfully developed the business of TWB, a...

Rachel Manley is the Head of Global Outreach for Save the Cord Foundation, a 501(c)(3) non-profit based out of the US and active globally. The Foundation advocates for umbilical cord blood education, awareness, research and legislation. Through educational programs such as "World Cord Blood...

Athanasios (Sakis) Mantalaris is Professor in the W.H. Coulter Department of Biomedical Engineering at Georgia Tech & Emory since August 2018. Prior to his move to Atlanta, he was Professor of BioSystems Engineering in the Department of Chemical Engineering at Imperial College London. He...

More than 25 years of experience in BioProcessing and Life Science Industry Proven track record in a variety of global leadership functions linked to go to market activities with major vendors to the industry (Millipore, Sartorius, Lonza) 

David J. Mazzo, PhD, was appointed as Caladrius' Chief Executive Officer and as a member of our Board of Directors on January 5, 2015. In addition, Dr. Mazzo was appointed as President of the Company in March 2017. Dr. Mazzo brings to the Company over 35 years of international experience in the ...

Neil McGowan graduated with a First Class BSc. (Hons.) in Immunology & Pharmacology from the University of Strathclyde in 1998, after which he gained a PhD in medical science (specifically bone cell biology) from the University of Aberdeen. He moved to London in 2002 to continue his work in the ...

Founder OpenCell London, where we build biotech labs in shipping containers. Prior founded another biotech "Cell-Free Technology" that developed high throughput protein analysis tools. Was a Wellcome Interdisciplinary Fellow developing hardware for synthetic biology at the University of...

Rob Meijer is CEO of Amphera BV. Amphera B.V., an advanced-clinical-stage biotechnology company, develops dendritic cell therapies for the treatment of cancer. Our lead indication is mesothelioma, a cancer of the lining of the lungs. MesoPher is autologous dendritic cells loaded with our...

Aline Miller, PhD, is Chief Executive Officer and Co-Founder of Manchester BIOGEL, a company specialising in providing engineered, self-assembling peptide hydrogels for 3D cell culture, 3D bioprinting and incorporation within medical devices. She currently oversees all aspects of the business from...

Assistant Professor of General Pathology and Immunology at the Department of Biology and member of UNESCO Interdisciplinary Chair of Biotechnology & Bioethics. She has a long specific track of research activities in the field of immunology of infectious diseases and other immunorelated...

Paolo is a healthcare investment and market access professional with more than 15 years of experience in both assessing and supporting access to innovative healthcare technologies. Since 2017, Paolo is EU Director Market Access and Members Relations at the Alliance for Regenerative Medicine (ARM)...

Dave Morris, PhD, is Vice President of Therapeutic Discovery at Precision BioSciences where he leads a team focused on the pharmacological profiling of ARCUS nucleases developed for specific genetic targets. With over 15 years of experience leading multi-disciplinary international line and...

David Morrow is Programme Manager Translational Medicine & Drug Development at EATRIS.David received a BSc (Hons) in Molecular Biology from University College Dublin in 2001 and a PhD in Vascular Biology from Dublin City University in 2006. This was followed by an American Heart Association...

Alexander Natz is the Secretary General of the European Confederation of Pharmaceutical Entrepreneurs (www.eucope.org) in Brussels and advises innovative pharmaceutical and biotech companies, including start-ups, in regulatory and pricing & reimbursement matters from the EU law and German law...

Jelena Ochs was awarded her degree in bio-engineering, majoring in »Bioprocess Engineering from the University of Stuttgart. In January 2016, she took up a position as a research associate in the IPT Production Technology group. After only one month, she was appointed Manager of the »Life Sciences ...

Dr. Steve Oh obtained his PhD from Birmingham University, UK (1990) and is the Director of Stem Cell Bioprocessing and Institute Scientist, Stem Cell Group. He has had several industry leadership roles e.g. Asia-Pacific Vice President of International Society of Cell and Gene Therapy (ISCT); Member ...

Daniel O’Mahony is a Partner at Seroba Life Sciences and brings a wealth of experience in product development, strategic planning, licensing, corporate venturing, intellectual property management and commercialisation.Daniel was involved in corporate venture at Elan Corporation from 1996-2003. He...

Dr Christina O’Neill is the CEO of VascVersa. VascVersa is a new spin out from Queen’s University Belfast (QUB). Christina was the postdoctoral research scientist working on Angicyte technology before spinning the company out. She has extensive experience in the vascular biology field, having...

Dominic O’Regan, through his company New Mosaic Ltd, works to help seed stage companies in the UK and Europe obtain investment and to commercialise towards exit or market.  This work is typically very collaborative, with close working relationships with the companies and others in his network to...

Sean Palecek is the Milton J. and Maude Shoemaker Professor and Vilas Distinguished Achievement Professor in the Department of Chemical & Biological Engineering at the University of Wisconsin – Madison. Sean’s lab studies how human pluripotent stem cells (hPSCs) sense and respond to...

Ioannis is an ATMP Bioprocess Research Coordinator at Prometheus, KU Leuven, Belgium. He has graduated in Chemical Engineering, from the University of Patras, Greece and obtained a Doctoral degree (MPhil and PhD) from the Department of Biochemical Engineering, University College London (UCL), UK -...

Since January 2017 Dr. Detlev Parow is Head of the Department of Medicines, Therapeutic Appliances and Remedies at DAK-Gesundheit in Hamburg. From 2010 to 2016 he was responsible for Care Management Development at DAK-G. From 2002 to 2009, he worked for Hamburg Münchener, initially leading the...

Currently the Head of Cancer Research UK GMP Biotherapeutics Development Unit. Leonard Pattenden's pharmaceutical experience is primarily in the development of a range of biomolecules such as therapeutic blood factors and monoclonal antibodies, but he also has a track record in viral vector and ...

C. David Pauza, PhD is Chief Science Officer for American Gene Technologies and former Professor of Medicine at the University of Maryland Medical School in Baltimore. Prior to joining AGT, Dr. Pauza was Associate Director for the university’s prestigious Institute of Human Virology and Co-Leader...

David Pearce, PhD, is President of Innovation and Research for Sanford Health.  He completed his undergraduate Bachelor of Science Degree with honors in biological sciences at Wolverhampton Polytechnic in 1986.  He gained his PhD in 1990 at the University of Bath, UK, and did postdoctoral training...

Adam Perriman is a Professor of Bioengineering at the School of Cellular and Molecular Medicine, University of Bristol. He is internationally distinguished for his pioneering research on the construction and study of novel synthetic biomolecular systems, and his research interests span the fields...

Steven Pincus is the Head of Science and Innovation for FUJIFILM Diosynth Biotechnologies Texas (FDBT). His is responsible for the evaluation of new technologies for Advanced Viral Therapies and establishing and maintaining collaborations to foster innovation and development of training programs...

His high education has been at the University of Rome Tor Vergata where he obtained in 2010 the bachelor’s degree of Biotechnology, and in 2012 the master’s degree in bioinformatics. During his thesis he collaborated with the Proxagen Ltd – Sofia, Bulgaria – to develop a software for the prediction ...

Roland Pochet, Ph.D., Honorary Professor of Cell Biology at the Faculty of Medicine of Université Libre de Bruxelles, is a neuroscientist who studies stem cell transplantation for amyotrophic lateral sclerosis. Pochet studied for two years in Israel under a European Molecular Biology Organization...

Avery D. Posey, Jr., Ph.D. is an Assistant Professor in the Department of Systems Pharmacology and Translational Therapeutics, at the Perelman School of Medicine, University of Pennsylvania. Dr. Posey trained as a postdoctoral fellow and instructor with Dr. Carl June from 2011-2019. Dr. Posey...

Martin Pule is Clinical Senior Lecturer in the Dept. of Haematology at UCL Cancer Institute and Honorary Consultant in Haematology at University College London Hospital. His research is focused on many aspects of genetic engineering of T-cells for cancer treatment, with a particular focus on...

Dr Qasim Rafiq is a Senior Lecturer (Associate Professor) in Cell & Gene Therapy Bioprocessing within the Department of Biochemical Engineering at University College London (UCL). Prior to this he was a Lecturer (Assistant Professor) in Bioprocess Engineering at Aston Medical Research...

Dr. A. Rahmo is CEO and cofounder of SMSbiotech, a California based company established in 2015. A. Rahmo finished his degree in Biochemistry at the Swiss Federal Institute of Technology in Zurich 1988, and completed his PhD at the University of Southern California in Los Angeles., he did his...

Lior Raviv joined Pluristem in 2011 and currently serves as Vice President of Development in charge on process & technology development and manufacturing sciences. Prior to that Mr. Raviv served as Projects manager & Product development Team leader at Pluristem in charge of new technologies ...

Ajan Reginald is a co-founder and the Chief Executive Officer of Celixir, which he originally founded under the name Cell Therapy Ltd in 2009 with Nobel Laureate Professor Sir Martin Evans.  Celixir is a British biotechnology company that discovers and develops life-saving and life-altering...

Research fields and achievementsPetra Reinke is Professor of Internal Medicine and Nephrology and since 2017 Director of the Berlin Center for Advanced Therapies (BeCAT). She is also Head of the GMP-Facility and of the research area “Immune Systems” at the BIH Center for Regenerative Therapies...

Al Ribickas is the BMT/QC Laboratories Manager in the Cell Therapies Facility at the Moffitt Cancer in Tampa Florida.  Al has provided leadership for cellular therapy facilities for over eighteen years. He attended the University of South Florida receiving a degree in Clinical Laboratory...

I gained my BS in Biotechnology and MS in Industrial Biotechnology at the University of Rome Tor Vergata. I did my PhD at the Albert-Ludwigs-Universität Freiburg in the lab of Prof. Toni Cathomen working on the pre-clinical development of HIV resistant genome edited human T cells. I did my...

I am responsible for the development and application of technologies in the area of precise genome engineering, human stem cell based disease models and transgenics in Discovery Sciences at Astrazeneca and the facilitating the exploitation of these technologies by our iMED disease focus areas for...

Nicolas Rousseau is a graduate from the French Engineering school CentraleSupélec. He has a biomedical engineering master from the University of Cambdrige. After a master thesis projet at the Pasteur Institute on gene therapy, he joined Jeanne Volatron, the CEO of EverZom to build the company. He...

Christoph focuses on investments in life sciences and digital health. He initially practised as a radiologist, before spending 3 years at Bain & Company. In 2006, he joined 3i working for their Healthcare Venture Capital after which he worked for General Electric's healthcare...

Mark Sawicki brings 15 years of business development and sales management experience, having consistently delivered on corporate revenue and market share goals in the pharmaceutical and biotechnology industries. Sawicki was most recently the chief business officer at AAIPharma Services...

David Schaffer is the Hubbard Howe Professor of Chemical and Biomolecular Engineering, Bioengineering, and Neuroscience at the University of California, Berkeley, where he also serves as the Director of the Berkeley Stem Cell Center. He received a B.S. from Stanford University in 1993 and a...

Dominic is a Partner of Syncona. Prior to joining Syncona, he worked in the life sciences team of strategy consultancy L.E.K. Consulting. Dominic received his PhD from the Department of Oncology at the University of Cambridge, where he was a Cancer Research UK scholar. He also holds a German Diplom ...

Stephanie Schorge has a PhD in Neuroscience from Brown University, and has a longstanding interest in how mutations alter neuronal excitability in neurological conditions. She came to UCL in 1999 for a 3 year postdoctoral position and never left. She is now Professor of Translational Neuroscience...

Dr.ir. Jan Schrooten is co-founder and CEO of Antleron, a young R&D company on a mission to enable personalized manufacturing 4.0 in the domain of advanced therapies. Antleron merges the potential of cells, biomaterials, biologics, 3D printing and bioreactors to accelerate the engineering of...

Margarida Serra is the Head of Stem Cell Bioengineering Laboratory from the Animal Cell Technology Unit of iBET. She is graduated in Biological Engineering at the Instituto Superior Técnico, and holds a PhD in Engineering and Technology Sciences, from NOVA University of Lisbon in 2011. She did part ...

Dr Maryam Shariatzadeh is an interdisciplinary bioengineering scientist, and a qualified pharmacist whose project focuses on development of ODE mechanistic modelling for T cell therapy manufacture to offer cost effective solutions in T cells / CAR T cells bioprocessing / process control and...

Ilya Shestopalov, PhD currently leads the cell analytics group within cellular process development at bluebird bio.  His research focuses on development of cell-based assays for hematopoietic stem/progenitor and CAR-T products.  Prior to bluebird bio, Dr. Shestopalov was a postdoctoral fellow in...

John Sinden cofounded Glialign Limited with Dr James Phillips in 2018. He has 20 years experience in the scientific development and commercialization of regenerative medicine products. He was a scientific co-founder of AIM-listed ReNeuron and from 1998 to April 2019 was CSO and was integral to all...

Yochi Slonim is a serial entrepreneur with a track record of over 30 years in software and biotech. As a Co-founder and CEO, he is driving the company's vision and strategy, fundraising, and partnering. Prior to Anima, Yochi has built several companies from their early stage, through all stages ...

Devyn joined Sigilon Therapeutics in early 2017 as Chief Strategy Officer and Head of Operations. In this role, he has led the development of the corporate strategy, portfolio strategy and other key strategy elements.  In addition, he is accountable for project management, intellectual...

Alan Smith, is currently the Executive Vice President Technical Operations at Bellicum Pharmaceuticals. He has broad experience in the cell therapy area with over 30 years working in various senior management roles in research and development, manufacturing and quality in cell and gene therapy...

Luce Sohier, holds a 5 year degree diploma in biochemistry and microbiology of the University of Nancy(ANSAIA), France. She has worked in upstream processing in a collaboration with Merck Millipore and Pall, and downstream processing with West and SCHOTT. Currently she is in charge of business...

Eric Soller, Ph.D., is BlueRock’s VP of corporate development and strategy. Dr. Soller led the launch of BlueRock as an entrepreneur-in-residence at Versant Ventures, a leading healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great healthcare...

Fatima Ann Sulaiman is the Head of Research and Services at Scleroderma and Raynaud’s UK (SRUK). SRUK is a patient focused organisation which funds research into scleroderma, a rare orphan auto immune condition. She is leading on the development and implementation of an innovative research strategy ...

Dr. Taiel completed her doctorate in Medicine with boardcertified in Ophthalmology from Lariboisiere Saint LouisUniversity, Paris, France, in 1993, and her Associate Professordegree in 1998. Dr Taiel completed her internship at academicParis hospitals, was an Associate Professor of...

Dr. Tarunina joined Plasticell Ltd as Principal Scientist in 2007 and become company’s Research Director in 2017. She has contributed to the development of the company’s CombiCult® technology platform and exemplified its broad applications in different areas of stem cell biology. Prior to joining...

Dr. Hartmut Tintrup is responsible since 3 years for Business Development & Partnering Activities for the EMEA region in the Lonza Cell & Gene Technologies Business Unit. He has more than 15 years experience in the biotech industry spanning leading positions in R&D, industrial sales as...

Pamela joined UCL Translational Research Office (TRO) in 2014 and has been leading the Translational Research group since 2016.    The TRO collaborates with academics, industry partners and external funding bodies, to facilitate the translation of UCL’s emerging research into therapies and medical...

Marc Turner is Professor of Cellular Therapy at the University of Edinburgh and Medical Director at the Scottish National Blood Transfusion Service. He qualified in Medicine from the University of Manchester in 1982 and trained in General Medicine and Haematology.  He obtained his PhD in human...

Evelina Vågesjö, CEO, Co-founder, PhD in physiology. Developed methods to steer immune cell functions and delineated a new mechanism of action during in tissue regeneration. BSc in Management Accounting, MBA-studies focus Finance and MnA.

Dr. van der Loo has been involved in the GMP manufacturing of viral vectors for early phase clinical trials since 2002. He received his PhD from the Erasmus University in Rotterdam in stem cell biology in 1995, completed a post-doctoral fellowship at Indiana University on a grant from the Howard...

Edward currently serves on the supervisory boards of Progentix Orthobiology, Cristal Therapeutics, Synaffix, Staten Biotechnology, Escalier BioSciences and Scenic Biotech. He served on the supervisory boards of BioCeros (sold in 2011), Noviogendix (acquired by MDxHealth) and was founding investor...

Dr David Venables is President, AskBio Europe, following the acquisition of Synpromics Ltd, where he was CEO. AskBio is a world leading gene therapy company with unrivaled technology and a promising therapeutic pipeline. As CEO of Synpromics, he led the growth of the company through a strategic...

Dr Vertès is Managing Director at NxR Biotechnologies, a boutique global consulting firm based in Basel, Switzerland, where he advises clients on strategy, business development, in/out-licensing, entrepreneurship and investment. He brings to his role extensive experience in the pharmaceutical and...

Professor Waddington leads a team which is focused upon preclinical models of gene therapy, particularly for perinatal gene delivery for early onset, debilitating and often lethal diseases including neurodegenerative diseases, inherited epilepsy and metabolic diseases. He is funded by the UK...

Darren Walsh is currently the Head of Market Access for EMEA at Orchard Therapeutics, a Global Fully Integrated Biotech Dedicated to Transforming the Lives of Patients with Rare Diseases Through Innovative Gene Therapies. He has 20+ year career in the biotech space working at a host of companies in ...

Michael D. West, Ph.D. has focused his academic and business career on the application of developmental biology to age-related degenerative disease. He is founder and CEO of AgeX Therapeutics, a biotechnology company focused on the emerging field of interventional gerontology. He formerly served as ...

Stefano has been working in  clinical research  for more than 20 years, mainly in GSK but also in Novartis and Aptuit, managing a portfolio of clinical projects and  leading a group of scientists accountable for the end to end operational management of the assigned clinical studies from concept...